{"id":"placebo-pill-imitating-pentoxiphylline","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL628","moleculeType":"Small molecule","molecularWeight":"278.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, this formulation contains no active pharmaceutical ingredient and produces no pharmacological effect. It is used in Phase 3 trials to serve as a control arm against pentoxifylline, which is a methylxanthine derivative that improves blood flow by reducing blood viscosity and increasing red blood cell deformability. The placebo allows researchers to isolate the true therapeutic effect of pentoxifylline from placebo response.","oneSentence":"This is a placebo pill designed to mimic pentoxifylline in appearance for use as a control in clinical trials.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:28:19.026Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trials (specific indication depends on the pentoxifylline trial being conducted)"}]},"trialDetails":[{"nctId":"NCT00561093","phase":"PHASE3","title":"Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2008-02","conditions":"Hypoalbuminemia, Protein-energy Malnutrition, Inflammation","enrollment":93}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-","inflammatory and appetite-stimulating pill while subjects undergo thrice","weekly hemodialysis and during the following non-dialysis day (6 days per week)"],"phase":"phase_3","status":"active","brandName":"Placebo pill imitating pentoxiphylline","genericName":"Placebo pill imitating pentoxiphylline","companyName":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","companyId":"lundquist-institute-for-biomedical-innovation-at-harbor-ucla-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo pill designed to mimic pentoxifylline in appearance for use as a control in clinical trials. Used for Control arm in Phase 3 clinical trials (specific indication depends on the pentoxifylline trial being conducted).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}